Effect of intra-arterial nimodipine on iatrogenic vasospasms during endovascular stroke treatment - angiographic resolution and infarct growth in follow-up imaging.


Journal

BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555

Informations de publication

Date de publication:
05 Jan 2023
Historique:
received: 11 10 2022
accepted: 27 12 2022
entrez: 5 1 2023
pubmed: 6 1 2023
medline: 10 1 2023
Statut: epublish

Résumé

The treatment of vasospasms during endovascular stroke treatment (EST) with intra-arterial nimodipine (NM) is routinely performed. However, the efficacy of resolving iatrogenic vasospasms during the angiographic intervention and the infarct development in follow-up imaging after EST has not been studied yet. Retrospective single-center analysis of patients receiving EST for anterior circulation vessel occlusion between 01/2015 and 12/2021. The primary endpoint was ASPECTS in follow-up imaging. Secondary endpoints were the clinical outcome (combined endpoint NIHSS 24 h after EST and difference between modified Rankin Scale (mRS) before stroke and at discharge (delta mRS)) and intracranial hemorrhage (ICH) in follow-up imaging. Patients with vasospasms receiving NM (NM+) or not (NM-) were compared in univariate analysis. Vasospasms occurred in 79/1283 patients (6.2%), who consecutively received intra-arterial NM during EST. The targeted vasospasm angiographically resolved in 84% (66/79) under NM therapy. ASPECTS was lower in follow-up imaging after vasospasms and NM-treatment (NM - 7 (6-9), NM + 6 (4.5-8), p = 0.013) and the clinical outcome was worse (NIHSS 24 h after EST was higher in patients treated with NM (median, IQR; NM+: 14, 5-21 vs. NM-: 9, 3-18; p = 0.004), delta-mRS was higher in the NM + group (median, IQR; NM+: 3, 1-4 vs. NM-: 2, 1-2; p = 0.011)). Any ICH (NM+: 27/79, 34.2% vs. NM-: 356/1204, 29.6%; p = 0.386) and symptomatic ICH (NM+: 2/79, 2.5% vs. NM-: 21/1204, 1.7%; p = 0.609) was equally distributed between groups. Intra-arterial nimodipine during EST resolves iatrogenic vasospasms efficiently during EST without increasing intracranial hemorrhage rates. However, patients with vasospasms and NM treatment show higher infarct growth resulting in lower ASPECTS in follow-up imaging.

Identifiants

pubmed: 36604639
doi: 10.1186/s12883-022-03045-x
pii: 10.1186/s12883-022-03045-x
pmc: PMC9814217
doi:

Substances chimiques

Nimodipine 57WA9QZ5WH

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5

Informations de copyright

© 2023. The Author(s).

Références

J Neurointerv Surg. 2014 Mar;6(2):83-6
pubmed: 23390038
Clin Neuroradiol. 2021 Sep;31(3):745-752
pubmed: 32894352
Stroke. 2001 Sep;32(9):2005-11
pubmed: 11546889
Front Neurol. 2021 May 14;12:661955
pubmed: 34054705
Stroke. 2015 Oct;46(10):2981-6
pubmed: 26330447
Neurol Res Int. 2013;2013:373458
pubmed: 24228177
J Stroke Cerebrovasc Dis. 2013 Jan;22(1):22-7
pubmed: 21719308
Stroke. 2020 Jul;51(7):1961-1968
pubmed: 32568643
Neuroradiology. 2019 Apr;61(4):461-469
pubmed: 30778621
J Neuroimaging. 2009 Jan;19(1):61-4
pubmed: 18801002
Int J Stroke. 2018 Jun;13(4):348-361
pubmed: 29171362
Br J Neurosurg. 2012 Aug;26(4):517-24
pubmed: 22303863
AJNR Am J Neuroradiol. 2001 Sep;22(8):1534-42
pubmed: 11559501
Neuroradiology. 2014 Jun;56(6):477-86
pubmed: 24687568
Crit Care. 2007;11(4):220
pubmed: 17705883
AJNR Am J Neuroradiol. 2014 Mar;35(3):524-8
pubmed: 24029392
J Neurosurg. 2010 Jun;112(6):1208-15
pubmed: 19835470
J Neurointerv Surg. 2021 Oct;13(10):912-917
pubmed: 34158401
J Neurol. 2017 Mar;264(3):432-436
pubmed: 27325355
Neuroradiology. 2014 Jun;56(6):467-76
pubmed: 24668181

Auteurs

Jessica Jesser (J)

Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.

Arne Potreck (A)

Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.

Dominik Vollherbst (D)

Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.

Fatih Seker (F)

Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.

Min Chen (M)

Department of Neurology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.

Silvia Schönenberger (S)

Department of Neurology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.

Thuy D Do (TD)

Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.

Martin Bendszus (M)

Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.

Markus A Möhlenbruch (MA)

Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.

Charlotte S Weyland (CS)

Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. charlotte.weyland@med.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH